Form 4: Stoke Therapeutics' Chief Medical Officer Reports Stock Transactions
SEC Form 4 Filing
Barry Ticho, Chief Medical Officer of Stoke Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On March 15, 2024, Barry Ticho acquired 13,100 shares of common stock and 13,100 restricted stock units.
- These restricted stock units vest annually beginning March 15, 2024.
- On March 19, 2024, Ticho disposed of 4,116 shares of common stock at a weighted average price of $6.0986 per share.
- The sale was mandated by the issuer to cover tax withholding liabilities related to the vesting of restricted stock units.
- Following these transactions, Ticho beneficially owns 11,469 shares of common stock and 39,300 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Acquisition of 13,100 shares of common stock and 13,100 restricted stock units; vesting of RSUs begins. |
| 03/19/2024 | Sale of 4,116 shares of common stock at an average price of $6.0986 per share. |
| 03/15/2027 | Expiration date of restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.